Evidence map›Paper›PMID 42011916›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

NSUN5 Attenuates Renal Injury and Ferroptosis in Hyperuricaemic Nephropathy Through YBX2-Dependent Stabilisation of SCD1 m5C Methylation.

Xiu-Xiu Song, Xiao-Guo Suo, Yue Yu, Kuo Zhang, Chen-Ao Li, Jie Wang, Hui-Xia Xu, Si-Yu Niu, Dong-Xue Lv, Zi-Hao He and 3 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xiu-Xiu SongSchool of Pharmacy (Anhui Medical University), Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
Xiao-Guo SuoSchool of Pharmacy (Anhui Medical University), Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
Yue YuSchool of Pharmacy (Anhui Medical University), Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
Kuo ZhangSchool of Pharmacy (Anhui Medical University), Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
Chen-Ao LiSchool of Pharmacy (Anhui Medical University), Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
Jie WangSchool of Pharmacy (Anhui Medical University), Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
Hui-Xia XuSchool of Pharmacy (Anhui Medical University), Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
Si-Yu NiuSchool of Pharmacy (Anhui Medical University), Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
Dong-Xue LvSchool of Pharmacy (Anhui Medical University), Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
Zi-Hao HeSchool of Pharmacy (Anhui Medical University), Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
Feng-He LiSchool of Pharmacy (Anhui Medical University), Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
Xiao-Ming MengSchool of Pharmacy (Anhui Medical University), Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.ORCID https://orcid.org/0000-0002-1166-561X
Juan JinSchool of Pharmacy (Anhui Medical University), Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.

Funding

National Natural Science Foundation of China 82473992
6 · The paper itself

Abstract

RNA 5-methylcytosine (m5C) modification plays a critical role in multiple diseases; however, its function in hyperuricaemic nephropathy (HN) remains unclear. Here, we show that renal m5C levels are markedly decreased and the m5C methyltransferase NOP2/Sun RNA methyltransferase 5 (NSUN5) is downregulated in HN mice. Conditional knock-in (cKI) mice and mouse tubular epithelial cells overexpressing NSUN5 exhibit resistance to uric acid (UA), thereby alleviating kidney injury, inflammation, and fibrosis in HN. Bisulphite sequencing coupled with RNA sequencing identifies stearoyl-CoA desaturase-1 (SCD1) as a direct NSUN5 target and reveals the involvement of NSUN5 in ferroptosis regulation. Mechanistically, NSUN5 installs m5C on SCD1 mRNA. The m5C reader YBX2 binds to the modified transcript, prolonging the half-life of SCD1 mRNA and enhancing its stability, thereby suppressing ferroptosis. Elevated SCD1 also inhibits NF-κB p65 phosphorylation and nuclear translocation, dampens inflammatory responses and promotes ABCG2-dependent UA excretion. Recombinant NSUN5 further ameliorates renal injury in HN. Our findings revealed a novel NSUN5-mediated mechanism and highlight a potential therapeutic target for HN.

Indexed as

FerroptosisHyperuricemiaKidney DiseasesMethyltransferasesAnimalsHumansMaleMiceRNA MethylationMethyltransferasesferroptosishyperuricaemic nephropathym5C methylationNSUN5SCD1

Identifiers

PMID42011916
PMCPMC13285163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.